Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV Prasad

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimilars, anticipating significant growth within five years. Generics and active pharmaceutical ingredients will continue to be major revenue sources. Dr Reddy's aims to compete in a biologics-led future by investing in research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vAW1EzD
via IFTTT